Designed to support insulin resistance, resistant weight loss, low energy and overall metabolic and mitochondrial health.
AM: 1 pack 30 min prior a meal (largest meal or meal with the highest carbohydrate)
- 1 ALA + Berberine
- 1 B Complex
- 1 Berberine + InSea 2
- 3 Fiber Lean
PM: 1 pack 30 min prior to a meal (largest meal or meal with the highest carbohydrate)
- 1 ALA + Berberine
- 1 Berberine + InSea 2
- 3 Fiber Lean
BEFORE BED: 1 pack
- 3 magnesium chelate
- 1 tummy tone probiotic
Berberine is a plant alkaloid derived from several different plant species that have been used in Ayurveda and traditional Chinese medicine for a variety of therapeutic applications, including supporting healthy blood glucose metabolism and a healthy insulin response (1). Researchers have hypothesized that the modulation of gut microbes may be one mechanism by which berberine affects blood glucose metabolism(2). Berberine has been observed to inhibit the expression of disaccharidases in the duodenum, resulting in less glucose being formed from carbohydrate digestion.
Studies in subjects with type 2 diabetes who were administered berberine doses ranging from 1,000 to 1,500 mg per day. The results demonstrated a reduction in HbA1C, fasting blood glucose, and postprandial plasma glucose levels (1).
The branded ingredient InSea2® is a blend of polyphenols derived from the wildcrafted brown seaweeds Ascophyllum nodosum and Fucus vesiculosus that are sustainably harvested from the North Atlantic Ocean. InSea2 plays a role in the inhibition of alpha-amylase and alpha-glucosidase, two key enzymes involved in the digestion and assimilation of starch and sugar. Clinical studies with InSea2 have shown an effect of reducing post-prandial blood glucose levels, improving insulin sensitivity, and maintaining optimal blood glucose metabolism (6,7).
A randomized, double-blind, placebo-controlled trial in dysglycemic patients (N = 65) evaluated InSea2 (combined with 7.5 mcg of chromium picolinate) on glycemic status over a six-month period. At the end of the study period, 18.2% of patients in the test group returned to normal glycemic status compared to no change in glycemic status in the placebo group. In addition, a significant number of subjects changed categorization from impaired fasting glycemia to impaired glucose tolerance, suggesting improvement in insulin sensitivity and glycemic status in the test group.
Overall, subjects in the InSea2 test group had statistically significant improved markers for glycemic health, whereas the placebo subjects—exposed to the same diet and physical activity program—showed a decline in glycemic health markers (6). A randomized, double-blind, placebo-controlled, crossover study in healthy subjects (N = 23) aged 19-59 years examined the impact of InSea2 on post load plasma glucose and insulin concentrations. Two capsules with 250 mg of InSea2 were consumed 30 minutes prior to a 50 g load of carbohydrate, and plasma glucose and insulin responses were measured over a three-hour period post-ingestion. Consumption of InSea2 showed a modulation of insulin homeostasis following ingestion of a carbohydrate-rich meal (7).
Berberine with InSea2 combines clinically studied levels of berberine and InSea2 and is formulated to support a healthy glycemic response to ingested foods while maintaining healthy blood glucose levels.
